A growing body of literature supports our observation that lung adenocarcinomas mutated for KRAS and with an activated NRF2 pathway have an altered tumor microenvironment that can, in part, be attributed to changes in tumor metabolism [16,17,18]. The gene discussed is KRAS; the disease is neoplasm.